Biomarkers for hepatocellular carcinoma: What’s new on the horizon?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers for hepatocellular carcinoma: What’s new on the horizon?
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 24, Issue 35, Pages 3974-3979
Publisher
Baishideng Publishing Group Inc.
Online
2018-09-19
DOI
10.3748/wjg.v24.i35.3974
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome
- (2018) Alyson P Black et al. CURRENT OPINION IN PHARMACOLOGY
- Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines
- (2018) Carmen Ayuso et al. EUROPEAN JOURNAL OF RADIOLOGY
- The role of molecular enrichment on future therapies in hepatocellular carcinoma
- (2018) Jean-Charles Nault et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
- (2018) Ioannis Zerdes et al. ONCOGENE
- Emerging biomarkers for immune checkpoint inhibition in lung cancer
- (2018) George Cyriac et al. SEMINARS IN CANCER BIOLOGY
- Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012
- (2017) Donna L. White et al. GASTROENTEROLOGY
- Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
- (2017) Alexander Gerbes et al. GUT
- AASLD guidelines for the treatment of hepatocellular carcinoma
- (2017) Julie K. Heimbach et al. HEPATOLOGY
- Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma
- (2017) Ao Huang et al. JOURNAL OF HEPATOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Global trends and predictions in hepatocellular carcinoma mortality
- (2017) Paola Bertuccio et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
- (2017) Galina Khemlina et al. Molecular Cancer
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Therapy for Hepatocellular Carcinoma: 2017 Update
- (2017) Masatoshi Kudo ONCOLOGY
- Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update
- (2017) Masatoshi Kudo ONCOLOGY
- Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids
- (2017) Wataru Okajima et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma
- (2017) Weiwei Zhai et al. Nature Communications
- Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
- (2017) Yuelong Liang et al. Cancer Medicine
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
- (2017) et al. JAMA Oncology
- Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population
- (2016) T. Duarte-Salles et al. Cancer Prevention Research
- CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma
- (2016) Anna Kakehashi et al. CANCER SCIENCE
- A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis
- (2016) Xavier Verhelst et al. CLINICAL CANCER RESEARCH
- Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21Waf/Cip1 stabilization by activating the ERK1/2-MAPK pathway
- (2016) Yonglong Zhang et al. HEPATOLOGY
- Functional imaging in liver tumours
- (2016) Maxime Ronot et al. JOURNAL OF HEPATOLOGY
- Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection
- (2016) Bingnan Zhang et al. Liver Cancer
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
- (2015) Andrea Wong et al. Journal of Translational Medicine
- Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment
- (2015) Francesca V. Negri et al. LIVER INTERNATIONAL
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis
- (2014) Wei-Kai Xiao et al. BMC CANCER
- Emerging trends in hepatocellular carcinoma incidence and mortality
- (2014) Basile Njei et al. HEPATOLOGY
- Novel Proteomic Biomarker Panel for Prediction of Aggressive Metastatic Hepatocellular Carcinoma Relapse in Surgically Resectable Patients
- (2014) Gek San Tan et al. JOURNAL OF PROTEOME RESEARCH
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects
- (2014) Seow Chong Lee WORLD JOURNAL OF GASTROENTEROLOGY
- Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis
- (2013) Toshiya Kamiyama et al. HEPATOLOGY
- Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
- (2013) Nicola Personeni et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Analysis of Protein-Protein Interactions in Cross-talk Pathways Reveals CRKL Protein as a Novel Prognostic Marker in Hepatocellular Carcinoma
- (2013) Chia-Hung Liu et al. MOLECULAR & CELLULAR PROTEOMICS
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
- (2012) Shunsuke Kondo et al. International Journal of Clinical Oncology
- NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma
- (2011) Jun Cheng et al. CANCER LETTERS
- Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma
- (2011) Tong Junrong et al. JOURNAL OF BIOSCIENCES
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- Detection of Hepatocellular Carcinoma Using Glycomic Analysis
- (2009) R. Goldman et al. CLINICAL CANCER RESEARCH
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started